Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human BRCA1 Antikörper:
anti-Mouse (Murine) BRCA1 Antikörper:
anti-Rat (Rattus) BRCA1 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal BRCA1 Primary Antibody für ChIP, ICC - ABIN450350
Arizti, Fang, Park, Yin, Solomon, Ouchi, Aaronson, Lee: Tumor suppressor p53 is required to modulate BRCA1 expression. in Molecular and cellular biology 2000
Show all 9 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für IHC (p), IP - ABIN445490
Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001
Show all 8 Pubmed References
Human Polyclonal BRCA1 Primary Antibody für FACS, WB - ABIN151683
Zaugg, Su, Reilly, Moolani, Cheung, Hakem, Hirao, Liu, Elledge, Mak: Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. in Proceedings of the National Academy of Sciences of the United States of America 2007
Show all 7 Pubmed References
Human Polyclonal BRCA1 Primary Antibody für IHC - ABIN965696
Kim, Xu, Kastan: Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. in Genes & development 2002
Show all 5 Pubmed References
Human BRCA1 Primary Antibody für IHC - ABIN965694
Arlt, Xu, Durkin, Casper, Kastan, Glover: BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. in Molecular and cellular biology 2004
Show all 5 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für CyTOF, FACS - ABIN152030
Okada, Ouchi: Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. in The Journal of biological chemistry 2003
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für ICC, FACS - ABIN152032
Martin, Nahas, Tunuguntla, Fike, Gatti: Assessing 'radiosensitivity' with kinetic profiles of γ-H2AX, 53BP1 and BRCA1 foci. in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody für ChIP, ICC - ABIN151868
Li, Ting, Zheng, Chen, Ziv, Shiloh, Lee, Lee: Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. in Nature 2000
Show all 3 Pubmed References
Polyclonal BRCA1 Primary Antibody für IF - ABIN4948304
Scully, Livingston: In search of the tumour-suppressor functions of BRCA1 and BRCA2. in Nature 2000
Show all 3 Pubmed References
Human Polyclonal BRCA1 Primary Antibody für IP, PLA - ABIN151492
Rusin, Zajkowicz, Butkiewicz: Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. in Mechanisms of ageing and development 2009
Show all 2 Pubmed References
Findings indicate a transcriptional axis of FOXP3 (zeige FOXP3 Antikörper)-BRCA1-miR (zeige MLXIP Antikörper)-155 in breast cancer cells and show that plasma miR (zeige MLXIP Antikörper)-155 may serve as a non-invasive biomarker for detection of early stage breast cancer.
Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility.
Clinical outcomes between placebo- and olaparib-treated patients with somatic BRCA1/2 mutations were similar to those with germline BRCA1/2 mutations, indicating that patients with somatic BRCA1/2 mutations benefit from treatment with olaparib.
Low BRCA1 gene expression is associated with breast cancer.
This is the first report that describes FANC as a causative gene for CVID (zeige TNFRSF13B Antikörper). We propose here that FA should be considered in the differential diagnosis of CVID (zeige TNFRSF13B Antikörper).
this study identified a germline missense variant on BRCA1 significantly associated with poor prognosis of pancreatic cancer patients in China
in nasopharyngeal carcinoma patients, ERCC1 and BRCA1 may be a predictor of response to platinum-based chemotherapy and concurrent radiochemotherapy.
The diagnostic value of BRCA promoter methylation analysis in distinguishing BRCA1/2-related and sporadic breast carcinomas is considerably dependent on the targeted CpG sites. These findings are important for adequate use of BRCA methylation analysis as a prescreening tool for germline genetic testing
Results show that amplification of targetable oncogenes is frequent in BRCA1/2 mutation negative MBCs and may identify MBC (zeige DOCK2 Antikörper) subsets characterized by aggressive phenotype that may benefit from potential targeted therapeutic approaches.
Results identified a large new rearrangement in BRCA1 gene in patient with hereditary breast and ovarian cancer syndrome. It shows a tandem duplication of exon 3 causing an in frame insertion of 18 amino acids within the protein.
Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle.
The gene-specific SNP marker analysis showed a significant association of BRCA1 C28300A with milk somatic cell scores.
In general, OC use, childbearing and breastfeeding do not differ between BRCA1/2 carriers and non-carriers with ovarian cancer. However, the effects of tubal ligation may differ between BRCA1 carriers and non-carriers.
Bovine BRCA1 was phosphorylated and nuclear speckling was enhanced in response to DNA-damaging agents.These results provide evidence that phosphorylation and nuclear relocalization are highly conserved features of the BRCA1 response to genotoxic stress.
Consensus-based recombinant adeno-associated virus-BRCA1 knock out virus vectors failed to induce BRCA1 knockout in Gottingen fibroblasts.
BRCA1, but not BRCA2, suppresses the formation of tandem duplications at a site-specific chromosomal replication fork barrier imposed by the binding of Tus proteins to an array of Ter sites. BRCA1 has no equivalent role at chromosomal double-stranded DNA breaks, indicating that tandem duplications form specifically at stalled forks.
Loss of p16INK4 protein (p16) transforms breast cancer 1 (Brca1)-deficient mammary epithelial cell (MEC (zeige CCL28 Antikörper)) and induces mammary tumors.
Brca1 is necessary for hematopoietic stem cells maintenance and normal hematopoiesis and that distinct mutations lead to different degrees of hematopoietic dysfunction.
TGFbeta (zeige TGFB1 Antikörper) stabilized the abundance of BRCA1 by reducing the abundance of microRNA-182 (miR (zeige MLXIP Antikörper)-182). Ectopic expression of BRCA1 or antagonism of miR (zeige MLXIP Antikörper)-182 in cultured TGFbeta (zeige TGFB1 Antikörper)-deficient mammary epithelial cells restored luminal lineage commitment.
BRCA1 inactivation can increase expression of miR (zeige MLXIP Antikörper)-155, contributing to cardiac hypertrophy. And Rev produces their beneficial effects partially by down-regulating miR (zeige MLXIP Antikörper)-155 expression, which might be a novel strategy for treatment of cardiac hypertrophy.
both murine Brca1185stop tumors and human BRCA1185delAG breast cancer cells express a new gene domain-less (RING-less) BRCA1 protein that mediated resistance to homologous recombination deficient-targeted therapies
Genomic instability can be rescued by deletion of Trp53bp1 (zeige TP53BP1 Antikörper), encoding the DNA damage response factor 53BP1 (zeige TP53BP1 Antikörper); mice expressing RING-less BRCA1 do not show an increased susceptibility to tumors in the absence of 53BP1 (zeige TP53BP1 Antikörper); Genomic instability in cells expressing RING-less BRCA1 correlates with loss of BARD1 (zeige BARD1 Antikörper) and a defect in restart of replication forks after hydroxyurea treatment
the aberrant proliferative capacity of Brca1(-/-) luminal progenitor cells is linked to the replication-associated DNA damage response, where proliferation of mammary progenitors is perpetuated by damage-induced, autologous NF-kappaB (zeige NFKB1 Antikörper) signaling.
We report here elevated recombination rates at telomeres in cells from human BRCA1 mutation carriers and in mouse embryonic stem cells lacking both copies of functional Brca1.
loss of Brca1, a tumor suppressor that functions in DNA damage repair, in the mammary epithelium induced senescence with induction of p16 and a decline of stem cell function, which was rescued by p16 loss.
MRN (Mre11 (zeige MRE11A Antikörper), Rad50 (zeige RAD50 Antikörper), and Nbs1 (zeige NLRP2 Antikörper)) complex, CtIP (zeige RBBP8 Antikörper), and BRCA1 are required for both the removal of Top2 (zeige TOP2 Antikörper)-DNA adducts and the subsequent resection of Top2 (zeige TOP2 Antikörper)-adducted DSB ends.
BRCA1-dependent helicase (zeige DNA2 Antikörper) unloading is a critical, early event in DNA interstrand crosslink repair.
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.
BRCA1/BRCA2-containing complex, subunit 1
, RING finger protein 53
, breast and ovarian cancer susceptibility protein 1
, breast and ovarian cancer sususceptibility protein 1
, breast cancer type 1 susceptibility protein
, protein phosphatase 1, regulatory subunit 53
, BRCA1 homologue
, breast cancer type 1 susceptibility protein homolog
, breast cancer 1, early onset
, BRCA1 homolog
, breast and ovarian cancer susceptibility protein
, breast cancer associated 1